For investors looking to balance the search for growth with a degree of caution, the "Growth at a Reasonable Price" (GARP) method provides a solid middle path. This process seeks to find companies that are increasing their earnings and revenue at a good rate, but whose stock prices are not too high. It is a way to bypass the speculation of extreme growth stocks while also avoiding companies that may be cheap but have no forward momentum. One instrument for using this method is the "Affordable Growth" stock filter, which selects for companies with good growth, firm profitability and financial soundness, and a stock price that seems fair. A recent name found by this filter is Globus Medical Inc , A (NYSE:GMED), a maker of musculoskeletal healthcare products.
Growth Path and Momentum
The central idea of any GARP method is, expectedly, growth. A company needs to show a clear capacity to get bigger, with a believable plan for future gains. Globus Medical’s fundamental report shows a solid growth record that fits this need.
- Good Past Results: The company has posted notable growth in recent years. Revenue has increased at an average yearly pace of 30.08%, which the report calls "very strong." More significantly, Earnings Per Share (EPS) has grown by an average of 22.84% each year.
- Recent Speed: This is not just about old performance. In the last year, growth pace stayed firm, with revenue rising by 16.65% and EPS jumping by a notable 27.39%.
- Future Projections: While analyst estimates point to a slowdown from these high past rates, the coming view is still good. EPS is predicted to grow by an average of 11.57% per year, and revenue is expected to rise by 7.38%. For a GARP investor, this mix of a firm past and a still-sound future path is important, as it implies the growth story is ongoing but may not be priced into an expensive stock.
Valuation: Judging the "Reasonable Price"
Finding growth is only part of the task, the "reasonable price" element is what makes GARP different from simple growth investing. A stock that costs too much can hurt even a good growth story. Globus Medical’s valuation numbers show a varied but finally positive image when seen from the GARP view.
- Comparative Value: While the company’s Price-to-Earnings (P/E) ratio of 21.77 may look high alone, setting is key. This ratio is lower than almost 80% of similar companies in the Health Care Equipment & Supplies field. The Price-to-Forward Earnings ratio of 19.27 shows a similar situation, being more appealing than over 80% of industry rivals.
- Wider Market View: Compared to the larger S&P 500, GMED’s valuation seems fair. Its normal P/E is near the market average, while its forward P/E is priced a bit lower.
- Cash Flow and EBITDA Measures: Other valuation tools may be more revealing. Looking at its Price-to-Free Cash Flow and Enterprise Value-to-EBITDA ratios, Globus Medical is priced lower than about 90% and 82% of its industry, in turn. This shows the market may be valuing it at a level below the company’s cash production and business earnings.
Basis of Profitability and Financial Soundness
Lasting growth at a fair price is seldom based on weak grounds. The GARP method inherently needs companies to be profitable and financially stable, which aids future growth without too much danger. Globus Medical does well here, getting high marks in its fundamental report.
Profitability Points:
- The company has very good margins, with a Profit Margin of 18.30% that is better than 94% of its industry.
- Its Return on Invested Capital (ROIC) of 9.75% is firm, beating almost 89% of similar companies and displaying recent gains.
- Importantly, the company has been reliably profitable with positive operating cash flow for at least the past five years.
Financial Soundness Notes:
- The balance sheet is strong, with no debt, a current ratio of 4.26, and a quick ratio of 2.74, showing enough cash to cover needs.
- This leads to a very high Altman-Z score of 11.31, pointing to very little short-term bankruptcy danger and doing better than over 92% of the industry.
These items are key for the affordable growth idea. High profitability indicates the company’s growth is effective and builds value for shareholders, while a very strong balance sheet gives the steadiness to handle economic changes and pay for future projects from within.
Final Thoughts and Next Steps
Globus Medical offers a solid example for the Growth at a Reasonable Price framework. The company displays a strong mix of quickening past growth and a good future view, meeting the main "growth" test. This growth is not valued at a high level compared to its industry, fitting the "reasonable price" need, particularly when looking at cash-flow valuations. Also, the investment case is supported by high-level profitability and a very firm, debt-free financial state, which lowers risk and aids lasting growth.
For investors wanting to see other companies that match this balanced picture of growth, value, and fundamental firmness, more examples can be seen by checking the Affordable Growth stock filter. A complete look at all the fundamental items discussed for GMED is in its full Fundamental Analysis Report.
Disclaimer: This article is for information only and is not financial advice, a suggestion to buy or sell any security, or a support of any investment plan. Investors should do their own study and think about their personal money situation and risk comfort before making any investment choices.
